Duchenne Muscular Dystrophy Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Sarepta Therapeutics, FibroGen, Capricor, Santhera Pharmaceutical, Catabasis Pharma

October 26 17:58 2022
Duchenne Muscular Dystrophy Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Sarepta Therapeutics, FibroGen, Capricor, Santhera Pharmaceutical, Catabasis Pharma
The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Duchenne Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Insights

 

Duchenne Muscular Dystrophy Overview

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in children. It is a genetic disorder characterized by progressive muscle degeneration and weakness and is one of nine types of muscular dystrophy.

 

Some of the key facts of the Duchenne Muscular Dystrophy Market Report: 

  • The Duchenne Muscular Dystrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • The total diagnosed prevalent population of Duchenne Muscular Dystrophy in the 7MM was 33,813 cases in 2021 
  • In March 2021, 2021 MDA Clinical & Scientific Conference took place. Major key players with their lead products namely vamorolone, Casimersenand others presented updated findings in an all-virtual environment, which included live-broadcast sessions, on-demand videos, virtual networking sessions, exhibits and poster sessions 
  • According to the National Organization for Rare Diseases (NORD), Duchenne Muscular Dystrophy is the most common childhood-onset form of muscular dystrophy and affects males almost exclusively 
  • Key Duchenne Muscular Dystrophy Companies: Sarepta Therapeutics, FibroGen, Capricor, Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco Cumberland Pharmaceuticals, and others
  • Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, Ifetroban, Pamrevlumab, and others 
  • The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females 

 

Get a Free sample for the Duchenne Muscular Dystrophy Market Report 

 

Key benefits of the Duchenne Muscular Dystrophy Market report:

  1. Duchenne Muscular Dystrophy market report covers a descriptive overview and comprehensive insight of the Duchenne Muscular Dystrophy Epidemiology and Duchenne Muscular Dystrophy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Duchenne Muscular Dystrophy market report provides insights on the current and emerging therapies.
  3. Duchenne Muscular Dystrophy market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Duchenne Muscular Dystrophy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Duchenne Muscular Dystrophy market.

 

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiological Insights 

 

Duchenne Muscular Dystrophy Market  

The dynamics of the Duchenne Muscular Dystrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Duchenne Muscular Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Duchenne Muscular Dystrophy Epidemiology Segmentation:

The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Duchenne Muscular Dystrophy
  • Prevalent Cases of Duchenne Muscular Dystrophy by severity
  • Gender-specific Prevalence of Duchenne Muscular Dystrophy
  • Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

 

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy market forecast 

 

Duchenne Muscular Dystrophy Therapies and Key Companies

  • Givinostat (ITF2357): Italfarmaco
  • ATL1102: Antisense Therapeutics
  • SRP-9001: Sarepta Therapeutics
  • Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma
  • Ifetroban: Cumberland Pharmaceuticals
  • Pamrevlumab: FibroGen

 

Duchenne Muscular Dystrophy Market Drivers

  • Robust pipeline activity
  • Upcoming launches and approval
  • Emergence of Gene and Exon-Skipping Therapy

 

Scope of the Duchenne Muscular Dystrophy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Duchenne Muscular Dystrophy Companies: Sarepta Therapeutics, FibroGen, Capricor, Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco Cumberland Pharmaceuticals, and others
  • Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, Ifetroban, Pamrevlumab, and others
  • Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
  • Duchenne Muscular Dystrophy Market Dynamics:  Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Duchenne Muscular Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Duchenne Muscular Dystrophy Market Access and Reimbursement 

 

Duchenne Muscular Dystrophy Market Barriers

  • High treatment Cost
  • Multidisciplinary care
  • Lack of treatment options for non-ambulant Duchenne Muscular Dystrophy patients

 

Table of Contents 

1. Duchenne Muscular Dystrophy Market Report Introduction

2. Executive Summary for Duchenne Muscular Dystrophy

3. SWOT analysis of Duchenne Muscular Dystrophy

4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance

5. Duchenne Muscular Dystrophy Market Overview at a Glance

6. Duchenne Muscular Dystrophy Disease Background and Overview

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Duchenne Muscular Dystrophy 

9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices

10. Duchenne Muscular Dystrophy Unmet Needs

11. Duchenne Muscular Dystrophy Emerging Therapies

12. Duchenne Muscular Dystrophy Market Outlook

13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2019–2032)

14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies

15. Duchenne Muscular Dystrophy Market Drivers

16. Duchenne Muscular Dystrophy Market Barriers

17.  Duchenne Muscular Dystrophy Appendix

18. Duchenne Muscular Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Duchenne Muscular Dystrophy treatment, visit @ Duchenne Muscular Dystrophy Medications

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market

  Categories: